Eisai Signs a License Agreement with FUJI YAKUHIN for Dotinurad to Treat Hyperuricemia and Gout in China

 Eisai Signs a License Agreement with FUJI YAKUHIN for Dotinurad to Treat Hyperuricemia and Gout in China

Eisai Signs a License Agreement with FUJI YAKUHIN for Dotinurad to Treat Hyperuricemia and Gout in China

Shots:

  • FUJI YAKUHIN to receive up front, development & commercial milestones and will manufacture the formulation of dotinurad and supply it to Eisai while Eisai will get exclusive development and marketing rights for therapy and will be responsible for regulatory submission in China
  • FUJI YAKUHIN is expecting the maximum value of dotinurad in China by leveraging Eisai’s expertise for global expansion of dotinurad. The collaboration will provide new treatment options for hyperuricemia and gout and improves QoL of patients in China
  • Dotinurad is selective URAT1 inhibitor, act by suppressing uric acid reabsorption and lowering blood uric acid levels

Click here ­to­ read full press release/ article | Ref: Eisai | Image: Eisai

Tuba Khan

Tuba Khan is an Editor and Digital Marketing expert at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in Lifesciences industry. She covers Pharma, Medical devices, Diagnostics and Digital health segment. Tuba also has an experience of digital and social media marketing and can run the campaign independently. She is also certified as a Digital marketer and social media marketer. She can be contacted on tuba@pharmashots.com

Related post